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Summary. Recombinant factor VIII (rFVIII) products
provide a safe and efficacious replacement therapy for
prevention and treatment of bleeding episodes in
patients with haemophilia A. The present
investigations from the multinational, open-label
guardianTM clinical trials assessed the haemostatic
response of turoctocog alfa (NovoEight), a rFVIII
product, in patients with severe haemophilia A
(FVIII ≤ 1%) undergoing surgery. All patients had a
minimum of 50 exposure days to any FVIII product
prior to surgery and no history of inhibitors. A total
of 41 procedures (13 orthopaedic, 19 dental and 9
general) were performed in 33 patients aged
4–59 years. Of the 41 procedures, 15 were major
surgeries in 13 patients and 26 were minor surgeries
in 21 patients. The success rate for haemostatic
response was 100% (success was defined as ‘excellent’
or ‘good’ haemostatic outcome). Turoctocog alfa
consumption on the day of surgery ranged from 27 to
153 IU kg1. The mean daily dose declined over time,
while retaining adequate FVIII coverage as measured
by trough levels. Overall, no safety issues were
identified. No thrombotic events were observed and
none of the patients developed FVIII inhibitors. In
conclusion, the present results show that turoctocog
alfa was effective in controlling blood loss by
obtaining a sufficient haemostatic response in patients
with severe haemophilia A undergoing surgery.
Keywords: clinical trial, haemophilia A, NovoEight,
recombinant factor VIII, surgery, turoctocog alfa
Introduction
Haemophilia A is a recessive X-linked congenital
bleeding disorder, caused by mutation in the coagula-
tion factor VIII (FVIII) gene on the long arm of the
X-chromosome. With a deficiency or absence of FVIII,
the activation of coagulation factor X (FX) becomes
severely impaired, and consequently, the thrombin
burst is delayed and insufficient for normal haemosta-
sis. Recurrent joint bleeds, most commonly in weight-
bearing joints, lead to chronic arthropathy, muscular
atrophy and deformities [1,2]. Major surgeries, such
as orthopaedic procedures, are often required by
patients with haemophilia A. Such surgeries carry the
risk of substantial blood loss and require haemostatic
control to be maintained for extended periods of time.
Despite the use of FVIII therapy, surgery in patients
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with haemophilia A remains challenging [3], and clini-
cal guidance on treatment during surgery procedures
in this patient population is still required.
The aim of this publication is to present the results
from three clinical trials assessing the safety and effi-
cacy of turoctocog alfa (NovoEight), a human
recombinant factor VIII (rFVIII) product [4,5], during
surgery in patients with severe haemophilia A.
Materials and methods
Patients
The present report includes information on surgeries
performed in the completed phase 3 guardianTM pro-
gramme (the guardianTM 1 trial in adolescent and adult
patients [6] and the guardianTM 3 trial in paediatric
patients [7]). In addition, information on surgeries per-
formed in the ongoing extension to these two trials
(guardianTM 2) is included as of 1 September 2012.
Minor surgery could be performed in all 3 trials,
while major surgery could be performed only in the
guardianTM 1 and 2 trials that were designed with sur-
gery sub-trials (definitions of minor and major surgeries
are provided in Table 1). Major surgery was not
allowed in the paediatric trial (guardianTM 3); the neces-
sity of major surgery in this trial led to withdrawal.
All patients had severe haemophilia A (FVIII ≤ 1%)
and were previously treated with at least 150
exposure days (adolescents and adults) or at least 50
exposure days (paediatric patients) to any FVIII prod-
uct and had no history of inhibitors. Patients with
previous significant thromboembolic events and
immune-deficient patients (defined by a CD4 + lym-
phocyte count below 200 lL1), were excluded from
the trial.
The guardianTM trials were approved by all relevant
independent ethics committees and institutional review
boards. All patients or their legally authorized repre-
sentatives provided written informed consent before
any trial-related activities. The trials were conducted
in accordance with the declaration of Helsinki [8] and
Good Clinical Practice [9], and are registered at www.
clinicaltrials.gov (NCT00840086, NCT00984126 and
NCT01138501).
Treatment
Peri-operative turoctocog alfa treatment could be
administered as bolus injections or continuous infu-
sion (Table 1). Dosing was determined by the investi-
gator based on the local practice. All patients received
a preoperative loading dose of turoctocog alfa imme-
diately prior to the surgical procedure. Following the
last surgically related turoctocog alfa dose, patients
reverted to preventive treatment with turoctocog alfa
under the guardianTM programme, in which safety was
monitored continuously.
Table 1. Definitions for major and minor surgeries*.
Major surgery† Minor surgery
Definition An invasive operative procedure where one
or more of the following occurred:
• A body cavity was entered
• A mesenchymal barrier was crossed
• A fascial plane was opened
• An organ was removed
• Normal anatomy was operatively altered
An invasive operative procedure in which only skin, mucous
membranes, or superficial connective tissue was manipulated
Expected duration of
surgery-related FVIII
treatment
At least 7 days including the day of surgery‡ Less than 7 days including the day of surgery
Treatment Bolus injection or continuous infusion Bolus injection
Dose level Dosing was determined by the investigator based on the
local practice. The protocols recommended to aim for
FVIII trough levels above 0.50 IU mL1 from the day
of surgery through day 7 post surgery
Dosing determined by the investigator based on the local practice
*The decision on whether a surgery was a minor or a major surgery was taken before the surgery was performed. Thus, in a few examples the criteria
for treatment duration of major surgeries (at least 7 days) and minor surgeries (less than 7 days) do not apply. More details were collected for major sur-
geries, and the surgeries were therefore not reclassified based on the duration.
†Major surgery was not allowed in the paediatric trial (guardianTM 3).
‡Patients receiving bolus injections could be discharged before day 7 post surgery, but were to have daily assessments at least until that day.
Table 2. Definition and evaluation of haemostatic response during and after surgery.
Evaluation During surgery After surgery
Excellent Blood loss less than expected Better than expected in this type of patient and procedure
Good Blood loss as expected As expected in this type of patient and procedure
Moderate Blood loss more than expected Less than optimal for the type of procedure, maintained without change of treatment regimen
None Uncontrolled bleeding Bleeding due to inadequate therapeutic response with adequate dosing; change of regimen required
Success was defined as ‘excellent’ or ‘good’ haemostatic outcome.
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Assessments and analysis
The primary objective of the clinical trial programme
was to evaluate the safety of turoctocog alfa, while
surgery-related efficacy and safety were assessed as
part of the secondary objectives.
Patient age and body mass index were recorded
prior to surgery. Efficacy assessments were performed
during and after the surgical procedures. For all sur-
geries, these assessments included haemostatic
response (Table 2) and turoctocog alfa consumption
on the day of surgery and in total. In addition, infor-
mation on duration of surgery, blood loss and number
of blood transfusions was collected for major surger-
ies. The haemostatic response was evaluated at the
end of the surgical procedure.
During the surgical period the following safety
assessments were performed: adverse events (daily),
vital signs, ECG, physical examination and safety lab-
oratory parameters. FVIII trough levels were measured
daily. Inhibitor assessment was performed both in the
surgical period as well as when preventive treatment
was resumed.
All evaluations were based on descriptive statistics.
Table 3. Patient demographics and types of surgical procedures.
Type of surgery
Major Minor Total
Number of patients 13 21 33
Age group
Children (≤11 years) 0 7 7
Adolescents (12–17 years) 1 0 1
Adults (≥ 18 years) 12 14 25
Race
Caucasian/White 12 13 24
Asian 1 8 9
Number of surgeries 15 26 41
Orthopaedic 13 0 13
Synovectomy 5 0 5
Arthroplasty* 8 0 8
Dental 0 19 19
General 2 7 9
Abdominal surgery† 1 0 1
Other‡,§ 1‡ 7§ 8
One patient had both major and minor surgery. This patient is counted
only once in the total column.
*Knee replacement (3), total hip (2), ankle arthroscopy (1), reduction of
finger fracture (1), elbow radial head excision (1).
†Pan-proctocolectomy, ileo-anal pouch.
‡Circumcision.
§Nail extirpation (2), central venous access device procedures (2), incision
of periumbilical abscess (1), closure of fistula (1) and debridement and
pus drainage (1).
Table 4. Details and outcomes of 15 major surgeries in 13 patients.
Major
surgeries
Surgery Turoctocog alfa exposure
Haemostatic
response
Procedure
Duration
Blood
loss
No. of
blood
transfusions
Days in
treatment*
Daily dose
(min–max)
Consumption†
on day
of surgery
Total
consumption†
During
surgery
After
surgery
h:mm mL IU kg1 IU kg1 IU kg1 Score (1–4)
1 Arthroprosthesis, knee 1:30 200 1 7 45 – 141 45 768 Good Good
2 Arthroscopy and
synovectomy,
partial meniscectomy
1:33 750 0 32 0 – 103 103 1468 Good Excellent
3 Arthroscopy, ankle 0:40 ND 0 7 27 – 55 27 219 Excellent Excellent
4 Circumcision 0:30 5 0 12 0 – 100 100 331 Excellent Excellent
5‡ Knee replacement 1:50 100 0 9 50 – 117 61 693§ Good Good
6‡ Elbow radial
head excision
7 Knee replacement 1:30 ND 0 44 0 – 61 61 1030 Excellent Excellent
8 Pan-proctocolectomy,
ileo-anal pouch
3:23 30 0 7 0 – 138 103 586 Excellent Good
9 Synovectomy, ankle 1:21 50 0 13 50 – 76 76 684 Excellent Good
10 Synovectomy, ankle 1:05 10 0 15 0 – 75 75 454 Excellent Good
11 Synovectomy, ankle 1:19 50 0 13 0 – 75 75 423 Excellent Excellent
12 Synovectomy, knee.
Extirpation of
osteosynthetic graft
1:00 200 0 24 0 – 98 98 1502 Good Good
13 Total hip arthroplasty 1:40 1000 3 21 0 – 153 153 1200 Excellent Excellent
14‡ Total hip
arthroprosthesis
3:25 1000 1 7 37 – 56 56 306 Good Excellent
15‡ Reduction of
finger fracture
Each shaded or white row represents one patient.
*A more frequent dosing regimen or higher doses could be given after return to preventive treatment.
†Dose administered as bolus injection, unless specified otherwise.
‡These surgeries were two simultaneous (but independent) operations performed in each patient, i.e. four operations in two patients. In these two patients
only the combined outcome was recorded.
§Combination of 28 IU kg1 administered as bolus injection and 665 IU kg1 administered as continuous infusion.
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Drug product
Turoctocog alfa is produced by expression in CHO
cells without any serum- or animal-derived compo-
nents. The turoctocog alfa drug product is a B-domain
truncated rFVIII molecule that consists of a heavy
chain, including a 21 amino acid sequence of the natu-
ral B domain, and a light chain. Upon thrombin acti-
vation, the B domain is removed, thereby rendering
the activated turoctocog alfa to be identical to native
activated FVIII. Turoctocog alfa can be monitored by
standard FVIII one-stage or chromogenic assays.
Turoctocog alfa was supplied as a sterile, freeze-
dried powder in single-use vials of 250 or 2000 IU per
vial to be reconstituted with 4.3 mL 0.9% sodium
chloride for injection.
Results and discussion
Patient demography and type of surgeries
A total of 15 major and 26 minor surgical procedures
were performed in 33 male patients (7 children, 1
adolescent and 25 adults). The patients had a median
(range) age of 24 (4–59) years and a median (range)
body mass index of 22.5 (14.8–32.6). The majority of
the surgeries were performed in Caucasians (24
patients) while the remaining 9 patients were Asians
(Table 3).
The performed surgeries included a wide spectrum
of procedures from uncomplicated dental procedures
to joint replacements and other orthopaedic surgeries,
to major abdominal surgery (Tables 4 and 5). In line
with the nature of the haemophilic condition, most
(13 of 15) of the major surgeries performed in the tri-
als were orthopaedic procedures related to haemophil-
ic arthropathy (Table 4). In two patients, two
independent major surgeries were performed simulta-
neously (Table 4). For these two patients, only one
combined outcome of their surgeries was recorded. A
total of 19 of the 26 minor surgeries were dental pro-
cedures (Table 5). This is consistent with the known
challenges connected with preventive dental care and
treatment in patients with haemophilia and the conse-
quent need for planned dental surgical intervention
[10]. The dental procedures covered a range of proce-
dures from uncomplicated extractions of deciduous
teeth to multiple extractions of molars. Two extrac-
tions were due to periodontitis.
Table 5. Details and outcomes of 26 minor surgeries in 21 patients.
Surgery procedure
Turoctocog alfa exposure
Haemostatic response
Days in treatment Daily dose (min–max) Total consumption* During surgery
days IU kg1 IU kg1 Score (1–4)
1 Catheter implementation 6 115–172 746 Good
2 Closure of fistula 6 36–71 304 Good
3 Debridement and pus drainage 1 50–50 50 Good
4 Dental extraction 1 22–22 22 Good
5 Dental extraction 1 52–52 52 Excellent
6 Dental extraction 1 24–24 24 Good
7 Dental extraction (impacted wisdom tooth) 1 25–25 25 Excellent
8 Dental extraction (impacted wisdom tooth) 1 25–25 25 Excellent
9 Dental extraction (2 premolars) 1 29–29 29 Excellent
10 Dental extraction (1 premolar) 1 28–28 28 Good
11 Dental extraction (2 deciduous teeth) 1 27–27 27 Excellent
12 Dental extraction (2 teeth due to caries) 1 87–87 87 Good
13 Dental extraction (1 tooth due to caries) 1 44–44 44 Good
14 Dental extraction (impacted wisdom tooth) 1 49–49 49 Good
15 Dental extraction (molar) 2 28–48 76 Good
16 Dental extraction (molar) and scaling 1 25–25 25 Good
17 Dental extraction due to caries 1 37–37 37 Excellent
18 Removal of ingrown nail 1 27–27 27 Excellent
19 Dental extraction due to periodontitis 5 79–158 606 Excellent
20 Dental extraction due to periodontitis 5 50–150 550 Excellent
21 Dental extraction due to periodontitis 2 100–100 200 Excellent
22 Dental root treatment 1 60–60 60 Excellent
23 Incision of periumbilical abscess 1 60–60 60 ND†
24 Ingrown nail extraction 1 34–34 34 Good
25 Removal of MediPort left subclavicular area 1 57–57 57 Excellent
26 Surgical extraction of tooth and radix of tooth 13‡ 0–60 513 Excellent
Each shaded or white row represents one patient. For dental extractions, the diagnosis, tooth type(s) and number of teeth are included in those cases
where the investigator had described this.
*All doses were administered as bolus injection.
†ND, not determined.
‡Due to the surgery type (surgical extraction of tooth and radix of tooth) this surgery was recorded as a minor surgery even though surgery-related turoc-
tocog alfa treatment was more than 7 days.
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Treatment
For major surgeries, doses were recorded daily follow-
ing surgery (Fig. 1). Four of the 13 patients undergo-
ing major surgery reverted to preventive treatment
after 7 days (Fig. 1 and Table 4). However, for three
of these four patients more frequent dosing or higher
doses were administered during preventive treatment
in the weeks after surgery than during their preventive
regimen before surgery at the discretion of the investi-
gator to aid postoperative healing. The extended sur-
gery-related treatment received by many patients
might be due to the practice of dosing turoctocog alfa
prior to physical therapy.
Turoctocog alfa consumption on the day of surgery
ranged from 27 to 153 IU kg1 (Table 4). The mean
daily dose declined over time (Fig. 1), while providing
adequate FVIII coverage as measured by trough levels
(Fig. 2). The increase in mean dose for those patients still
in surgery-related treatment observed after day 10
(Fig. 1) might be explained by some patients having days
without treatment followed by days on treatment or be
due to the decrease in the number of patients remaining
in surgery-related treatment, since those remaining were
likely using more factor than those not remaining. The
total median (range) consumption of turoctocog alfa
was 684 (219–1502) IU kg1 for major surgeries and
49.5 (22–746) IU kg1 for minor surgeries.
Antithrombotic prophylaxis was allowed but was
not administered to any patients. An antifibrinolytic
agent (tranexamic acid) was used in several cases dur-
ing and after surgery.
Clinical efficacy
The success rate for haemostatic response during and
after surgery was 100%. For all major surgeries, the
haemostatic response was rated ‘excellent’ (8 of 13
during surgery and 7 of 13 after surgery) or ‘good’ (5
of 13 during surgery and 6 of 13 after surgery). For
minor surgeries (which were rated only during sur-
gery), half (13 of 26) were rated as ‘excellent’. The
remaining surgeries were rated as ‘good’, except one
clinical assessment that was not determined (Fig. 3).
Similar haemostatic results have been reported for
other commercially available FVIII products [11–13].
A known limitation of comparisons of reported hae-
mostatic responses is that the definition given to each
of the treatment outcomes often differs between trials
and is largely subjective [14]. In the guardianTM pro-
gramme, the 4-point scale used to assess haemostatic
response during and after surgery was similar to the
assessment scales used in surgery trials with other
FVIII products, allowing comparisons between treat-
ment outcomes.
A notable result in this study was a 23-year-old
patient who underwent complex gastro-intestinal sur-
gery of more than 3 h duration with only minor blood
loss and with ‘excellent’ and ‘good’ haemostatic out-
come during and after surgery, respectively.
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Two patients had a blood loss of 1000 mL: one
55-year-old polytrauma patient undergoing two com-
bined procedures of total hip arthroprosthesis and
reduction of finger fracture and a 25-year-old patient
undergoing total hip arthroplasty. These two patients
accounted for 4 of 5 blood transfusions given for all
major surgery patients.
Clinical safety
Safety was assessed in all 33 treated patients. No
safety issues were identified. All patients undergoing
major surgery continued preventive treatment after
their surgery. Except from two patients with less than
2 months of preventive treatment after their surgery,
all other patients received preventive treatment for
more than 6 months after their surgery. None of the
patients developed FVIII inhibitors during the surgery
period or when preventive treatment was resumed
[6,7]. Furthermore, no postoperative bleeding compli-
cations were reported. A total of 5 adverse events
were recorded in 5 patients during major surgery (par-
aesthesia, haemorrhage, allergy to chemicals, arthral-
gia and vomiting). All events were mild or moderate
in severity and all events were evaluated by the inves-
tigator as unlikely to be related to the trial product.
All patients, except the patient with allergy, recovered
fully from these adverse events. No thrombotic events
were recorded.
One death occurred during the guardianTM 2 trial.
This patient underwent emergency surgery due to a
traumatic injury, but due to emergency circumstances,
no information about the haemostatic response was col-
lected and this patient is therefore not included in the
33 patients described in this paper. This patient received
turoctocog alfa treatment pre- and postoperatively, until
he died 2 days after arrival at the hospital. His death
was assessed as unrelated to the trial drug. No other
fatal events occurred during the guardianTM trials.
Conclusion
The guardianTM trials investigated the safety and effi-
cacy of turoctocog alfa in more than 200 patients. In
the present paper we describe the safety and efficacy
of turoctocog alfa during 41 surgeries, including 15
major surgeries in 13 patients. Although limited in
number, the procedures cover a wide surgical spec-
trum ranging from dental procedures to major abdom-
inal surgery. The results from the present study show
that turoctocog alfa is effective and well-tolerated
when used across a wide range of surgical procedures.
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